CYTK Q4 2024 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+912.4% YoY

Gross Profit

-$77M-453.1% margin

Operating Income

-$139M-821.4% margin

Net Income

-$150M-886.3% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+3555.9%

Cash Flow

Operating Cash Flow

-$66M

Free Cash Flow

-$67M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.5B

Stockholders' Equity

-$135M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$2M	+912.4%
Gross Profit	-$77M	-$83M	+7.9%
Operating Income	-$139M	-$127M	-9.1%
Net Income	-$150M	-$137M	-9.6%